VIVIAN YOUNG: Open Payments
NPI 1699312926 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 22 payments from 7 companies in 2025. Trend: 2023 $585 · 2024 $407 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $191 |
| Alkermes, Inc. | 3 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $115 |
| E.R. Squibb & Sons, L.L.C. | 4 | $99 |
| ABBVIE INC. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
Products named: CAPLYTA, LYBALVI, COBENFY, ABILIFY ASIMTUFII, VRAYLAR, REXULTI, ARISTADA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
